Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
C-Lecta GmbH currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of 2 pending office actions suggests a focused presence in this technical field. For a practitioner, managing these 2 pending office actions requires a strategy that addresses the specific requirements of each assigned examiner to ensure successful prosecution outcomes. The concentration in Biotechnology & Pharmaceuticals defines the technical scope of the current applications at the patent office.
The prosecution is distributed across 2 distinct examiners and 2 distinct art units. The busiest examiner, TSAY, MARSHA M, is responsible for 1 pending office action. Because TSAY, MARSHA M is one of the 2 distinct examiners involved, their individual examination style will influence the portfolio's progress. The presence of 2 distinct art units indicates that the technical subject matter is split between different specialized groups at the patent office. This distribution allows for a diversified approach to the examination process.
Practitioners should review the past trends associated with TSAY, MARSHA M to better prepare for the prosecution of the 1 pending office action under their review. This engagement within the Biotechnology & Pharmaceuticals sector allows for a tailored approach to each application. By focusing on the 2 distinct examiners, the company can adapt its responses to the specific legal interpretations favored by each individual. The outcome of these matters will be an indicator of the company's success in this field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
| KERSHAW, KELLY P | 1 | 17.7% | +16.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718823 | GLUCOSE ISOMERASES | TSAY, MARSHA M | — |
| 18682841 | METHOD FOR THE REMOVAL OF ACRYLAMIDE FROM FOODS AND STIMULANTS | KERSHAW, KELLY P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718823 | GLUCOSE ISOMERASES | TSAY, MARSHA M | — |
| 18682841 | METHOD FOR THE REMOVAL OF ACRYLAMIDE FROM FOODS AND STIMULANTS | KERSHAW, KELLY P | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718823 | GLUCOSE ISOMERASES | TSAY, MARSHA M | 1656 | §103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18682841 | METHOD FOR THE REMOVAL OF ACRYLAMIDE FROM FOODS AND STIMULANTS | KERSHAW, KELLY P | 1791 | §103 | Non-Final OA | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialC-Lecta GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Marsha M Tsay has the most, with 1 of C-Lecta GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
